ArticleJournal of neuro-oncology2026
Impact of 5-ALA and sodium fluorescein on FLAIR volume extent of resection and survival in IDH-wildtype glioblastoma.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to determine whether the choice of fluorophore (5-aminolevulinic acid [5-ALA], sodium fluorescein [SF], or their combination) influences the extent of resection (EOR) of FLAIR-hyperintense regions and, consequently, patient survival in IDH-wildtype glioblastoma.
methodsThis single-center retrospective study included 154 adult patients who underwent surgical resection of supratentorial glioblastoma between January 2021 and January 2023. Patients received 5-ALA (n = 63), SF (n = 69), or both (n = 22), depending on institutional drug availability over the study period. Volumetric analysis was performed using semi-automated segmentation on preoperative and early postoperative MRI. EOR was calculated separately for contrast-enhancing (CE) and FLAIR components. Survival outcomes were assessed using Kaplan-Meier and Cox proportional hazards analyses.
resultsNo statistically significant differences were observed between fluorophore groups regarding EOR-CE (p = 0.298), EOR-FLAIR (p = 0.060), or EOR-total (p = 0.293). However, 5-ALA use was associated with significantly improved progression-free survival (median 8.5 vs. 6.0 months; HR 1.89, 95% CI 1.26-2.81, p = 0.002) and overall survival (median 17.0 vs. 11.0 months; HR 2.32, 95% CI 1.33-4.04, p = 0.003) compared with SF. The survival advantage remained significant after adjustment for age, KPS, MGMT status, and adjuvant treatment (p < 0.05).
conclusionWhile no significant differences in FLAIR volume resection were observed between fluorophores, 5-ALA was associated with longer PFS and OS. The association persisted in multivariable models adjusting for residual tumor volumes, continuous EOR and RANO resect category. This may reflect a more biologically selective resection within the FLAIR-hyperintense region, a hypothesis that remains to be tested prospectively.
Indexed as
Identifiers
42749959What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.